Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Duchenne muscular dystrophy epidemiology and demographics

Introduction

Overview

Overview

The incidence of Duchenne muscular dystrophy is approximately 20 per 100,00 births worldwide. In 2010, the prevalence of Duchenne/ Becker muscular dystrophy was estimated to be 1.38 per 10,000 male individuals, ages 5 to 24 years. The mortality rate of Duchenne muscular dystrophy is 100%. The symptoms of Duchenne muscular dystrophy commonly presents in children younger than 5 years of age. Duchenne muscular dystrophy usually affects individuals of the Hispanic race. Non-Hispanic white or black individuals are less likely to develop DMD. Since the disease is X-link recessive, almost all of the patients are male but we may have some female carriers with symptoms as well.

Epidemiology and Demographics

Epidemiology and Demographics

Incidence

Prevalence

Case-fatality rate/Mortality rate

Age

Race

  • Duchenne muscular dystrophy usually affects individuals of the Hispanic race. Non-Hispanic white or black individuals are less likely to develop DMD.

Gender

References

References

  1. ↑ Stark AE (November 2015). “Determinants of the incidence of Duchenne muscular dystrophy”. Ann Transl Med. 3 (19): 287. doi:10.3978/j.issn.2305-5839.2015.10.45. PMC 4671860. PMID 26697447.
  2. ↑ Ryder, S.; Leadley, R. M.; Armstrong, N.; Westwood, M.; de Kock, S.; Butt, T.; Jain, M.; Kleijnen, J. (2017). “The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review”. Orphanet Journal of Rare Diseases. 12 (1). doi:10.1186/s13023-017-0631-3. ISSN 1750-1172.
  3. ↑ Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J (March 2015). “Prevalence of Duchenne and Becker muscular dystrophies in the United States”. Pediatrics. 135 (3): 513–21. doi:10.1542/peds.2014-2044. PMC 4477633. PMID 25687144.
  4. ↑ Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J (March 2015). “Prevalence of Duchenne and Becker muscular dystrophies in the United States”. Pediatrics. 135 (3): 513–21. doi:10.1542/peds.2014-2044. PMC 4477633. PMID 25687144.
  5. ↑ Yoshioka, Mieko (2008). “Clinically manifesting carriers in Duchenne muscular dystrophy”. Clinical Genetics. 20 (1): 6–12. doi:10.1111/j.1399-0004.1981.tb01799.x. ISSN 0009-9163.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.